Jim Meehan

NEW DELHI: Ranbaxy Laboratories on Monday announced that it has received tentative approval from the US Food and Drug Administration to manufacture and market Fenofibrate tablets. According to a company spokesperson, the pharma major has received approval for 54mg, 107mg and 160 mg. Fenofibrate is indicated for treatment of hypercholesterolemia and its total market is estimated at 675 million dollar. Commenting on the approval, Jim Meehan, Vice President, sales and marketing, Ranbaxy...

NEW DELHI: Drug maker Ranbaxy Laboratories on Monday said it has received approval from the US drug regulator for manufacturing and marketing the generic version of Robinul tablets, used in the treatment of peptic ulcer. The company has received approval from the US Food and Drug Administration (FDA) to manufacture and market Glycopyrrolate tablets in the strengths of 1 mg and 2 mg, Ranbaxy Laboratories said in a statement. Ranbaxy formulations are...

NEW DELHI: Ranbaxy on Thursday said it has received US Food and Drug Administration approval to manufacture and market Clorazepate Dipotassium tablets indicated for treatment of anxiety disorders. Clorazepate Dipotassium has been determined to be bioequivalent to Ovation Pharmaceuticals' Tranxene Tablets, 3.75mg, 7.5mg, and 15mg, a Ranbaxy release said here. "We look forward to introducing this product in the market within the next 60 days or sooner," company vice president for...

MUMBAI: Ranbaxy Laboratories has received tentative approval from the US Food and Drug Administration to manufacture and market valsartan tablets, 40 mg, 80 mg, 160 mg and 320 mg. Valsartan is indicated for the treatment of hypertension alone or in combination with other anti-hypertensive agents. It is also indicated for the treatment of heart failure. Total annual sales of Valsartan tablets was $1.3 billion as at June 2007. "Ranbaxy was...

MUMBAI: Shares of Ranbaxy Laboratories gained over 3 per cent after the pharmaceutical major announced the launch of a generic version of an ulcer pill Prilosec in the United States under an agreement with AstraZeneca. Omeprazole is the generic name of Prilosec. Prilosec 40 mg had sales of $204.2 million in the US market, Ranbaxy said in a statement citing IMS March 2008 data. "We welcome the opportunity to market an authorized generic of Omeprazole 40 mg...

MUMBAI: Ranbaxy Laboratories has received approval from the US Food and Drug Administration to manufacture and market Cefuroxime Axetil for Oral Suspension USP, 125 mg/5mL and 250 mg/5mL, which will be the first generic formulation on the market. The USFDA has determined that, the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect with reference listed drug Ceftin by GlaxoSmithKline. Total annual market sales for Cefuroxime...

NEW DELHI: Pharmaceutical company Ranbaxy Laboratories said today it has received tentative approval from US Food and Drug Administration to manufacture and market 'Metformin Hydrochloride' extended release tablets. Ranbaxy got the approval from the office of the generic drug of the US Food and Drug Administration to produce and sell the drug, a company press release said here. The total sales for all forms of 'Metformin' is around $1.6 billion with sales of $452.4 million for the...

NEW DELHI: Drug maker Ranbaxy Laboratories on Monday said it has received approval from the US drug regulator for manufacturing and marketing the generic version of Robinul tablets, used in the treatment of peptic ulcer. The company has received approval from the US Food and Drug Administration (FDA) to manufacture and market Glycopyrrolate tablets in the strengths of 1 mg and 2 mg, Ranbaxy Laboratories said in a statement. Ranbaxy formulations are...

NEW DELHI: Ranbaxy Laboratories Ltd on Tuesday launched its approved generic formulation of Clarithromycin immediate release (IR) tablets in the US market. The Office of Generic Drugs, US Food and Drug Administration has determined that Ranbaxy's Clarithromycin tablets of 250 mg and 500 mg formulation can be expected to have the same therapeutic effect as an equivalent dose of Abbott's Biaxin Filmtab, the company informed the Bombay Stock Exchange. "Our plans are to bring...

NEW DELHI: Pharmaceutical major Ranbaxy on Thursday said it has entered into a strategic alliance with Mumbai-based Ipca Laboratories to develop generic drugs. The company has also received the USFDA approval for edema treatment drug Furosemide tablets. Under the alliance with Ipca, the Mumbai-based firm would develop generic drugs, which would be marketed in the US by Ranbaxy. Ranbaxy would file for regulatory approval and support...

NEW DELHI: Ranbaxy Laboratories Ltd on Thursday said it has received tentative approval from the US Food and Drug Administration to manufacture and market Glimepiride tablets of 1 mg, 2 mg, 4 mg and 8 mg. "This product represents an interesting opportunity for Ranbaxy in which we will offer four strengths of this oral hypoglycemic agent to support patient compliance. The product will be launched following final approval from the FDA on October 6, 2005," said Jim Meehan, Vice President of Sales and...

MUMBAI: Ranbaxy Laboratories has received tentative approval from the US Food and Drug Administration to manufacture and market valsartan tablets, 40 mg, 80 mg, 160 mg and 320 mg. Valsartan is indicated for the treatment of hypertension alone or in combination with other anti-hypertensive agents. It is also indicated for the treatment of heart failure. Total annual sales of Valsartan tablets was $1.3 billion as at June 2007. "Ranbaxy was the...

GURGAON: Pharma major Ranbaxy Laboratories Limited (RLL) has received approval from the US Food and Drug Administration to manufacture and market Hydrocodone Bitartrate and Acetaminophen Tablets USP in variable strengths. "Hydrocodone Bitartrate and Acetaminophen Tablets are indicated for the relief of moderate to moderately severe pain and Ranbaxy is pleased to receive final FDA approval for multiple strengths of this product. These approvals further...

MUMBAI: Ranbaxy Laboratories said on Tuesday, it has received the final approval from US Food and Drug Administration (FDA) to make and sell hypertension drug, Amlodipine Besylate tablets in America. The approval was given for multiple strengths of tablets in 2.5 mg (base), 5 mg (base) and 10 mg (base), Ranbaxy said in a filing to Bombay Stock Exchange. "We are pleased to receive this final FDA approval for Amlodipine Besylate tablets, which represents Ranbaxy's 115th...

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories, has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Tamsulosin Hydrochloride Capsules, 0.4 mg. Tamsulosin HCl capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia. Total annual market sales for Flomax(R), Tamsulosin HCl capsules were $1.1 billion. "This tentative approval granted by the FDA...

MUMBAI: Ranbaxy Laboratories on Friday said its US subsidiary Ranbaxy Pharmaceuticals Inc (RPI) has received tentative nod from United States Food and Drug Administration (USFDA) for manufacturing and marketing Fexofenadine Hydrochloride tablets, used in treatment of allergies. "This product represents a future opportunity for Ranbaxy and will be launched following final approval from the FDA," RPI Vice President (Sales and Marketing) Jim Meehan said in a...

NEW DELHI: Pharmaceutical major Ranbaxy on Thursday said it has entered into a strategic alliance with Mumbai-based Ipca Laboratories to develop generic drugs. The company has also received the USFDA approval for edema treatment drug Furosemide tablets. Under the alliance with Ipca, the Mumbai-based firm would develop generic drugs, which would be marketed in the US by Ranbaxy. Ranbaxy would file for regulatory approval and support manufacturing...